Drug development in many areas of internal medicine is thriving, with companies expanding their pipelines in cardiometabolic, auto-immune or kidney diseases. Various rare but devastating conditions are also the focus of the industry, with a number of orphan drugs rapidly progressing through clinical development.
tranScrip’s expertise covers small molecules as well as monoclonal antibodies, cell therapy, antisense oligo-nucleotides and gene therapy. We are helping our clients seize opportunities and meet their development goals by challenging the current clinical and regulatory paradigms.
Read the full brochure here.
We have teams of life science and R&D experts to help achieve your goals and seize opportunities. Whatever your project requires, we have the people to meet your needs.